| [1] |
American Psychiatric Association. Diagnostic and statistical manual of mental disorders[M]. 5th ed. Arlington: American Psychiatric Association, 2013.
|
| [2] |
Brailean A, Curtis J, Davis K, et al. Characteristics, comorbidities, and correlates of atypical depression: evidence from the UK Biobank Mental Health Survey[J]. Psychol Med, 2020, 50(7): 1129-1138.
|
| [3] |
Cheung M M S, Lam S P, Chau S W H, et al. Hypersomnolence is associated with non-remission of major depressive disorder[J]. Sleep Med, 2024, 119: 35-43.
|
| [4] |
Hein M, Lanquart J P, Loas G, et al. Prevalence and risk factors of excessive daytime sleepiness in major depression: a study with 703 individuals referred for polysomnography[J]. J Affect Disord, 2019, 243: 23-32.
|
| [5] |
Chen Y, Zhang L F, Hu S F, et al. Status and correlates of hypersomnia in hospitalized patients with unipolar depression: Beijing, Henan, and Shandong, China, August 2019‒March 2021[J]. China CDC Week, 2021, 3(42): 879-882.
|
| [6] |
Bhachech H, Nath K, Sidana R, et al. Personalized approach in the management of difficult-to-treat and treatment-resistant depression with second-generation antipsychotics: a Delphi statement[J]. Cureus, 2024, 16(1): e52878.
|
| [7] |
Pearson O, Uglik-Marucha N, Miskowiak K W, et al. The relationship between sleep disturbance and cognitive impairment in mood disorders: a systematic review[J]. J Affect Disord, 2023, 327: 207-216.
|
| [8] |
Carey M G, Al-Zaiti S S, Dean G E, et al. Sleep problems, depression, substance use, social bonding, and quality of life in professional firefighters[J]. J Occup Environ Med, 2011, 53(8): 928-933.
|
| [9] |
Rethorst C D, Greer T L, Toups M P, et al. IL-1β and BDNF are associated with improvement in hypersomnia but not insomnia following exercise in major depressive disorder[J]. Transl Psychiatry, 2015, 5(8): e611.
|
| [10] |
Sunderajan P, Gaynes B N, Wisniewski S R, et al. Insomnia in patients with depression: a STAR*D report[J]. CNS Spectr, 2010, 15(6): 394-404.
|
| [11] |
Kwaśna J, Kwaśny A, Wilkowska A, et al. Residual hypersomnia in unipolar and bipolar depression: a systematic review[J]. World J Biol Psychiatry, 2024, 25(10): 575-591.
|
| [12] |
Manwaring J L, Blalock D V, Duffy A, et al. An examination of adults with atypical anorexia nervosa at admission to treatment at higher levels of care: an attempt to increase diagnostic clarity[J]. Int J Eat Disord, 2024, 57(4): 848-858.
|
| [13] |
Antonietta Furio M, Popovic D, Vieta E, et al. Characterization of rapid cycling bipolar patients presenting with major depressive episode within the BRIDGE-Ⅱ-MIX study[J]. Bipolar Disord, 2021, 23(4): 391-399.
|
| [14] |
Thase M E. Atypical depression: useful concept, but it's time to revise the DSM-Ⅳ criteria[J]. Neuropsychopharmacology, 2009, 34(13): 2633-2641.
|
| [15] |
Scott J, Byrne E, Medland S, et al. Short communication: self-reported sleep-wake disturbances preceding onset of full-threshold mood and/or psychotic syndromes in community residing adolescents and young adults[J]. J Affect Disord, 2020, 277: 592-595.
|
| [16] |
Rumble M E, White K H, Benca R M. Sleep disturbances in mood disorders[J]. Psychiatr Clin N Am, 2015, 38(4): 743-759.
|
| [17] |
Pandi-Perumal S R, Monti J M, Burman D, et al. Clarifying the role of sleep in depression: a narrative review[J]. Psychiatry Res, 2020, 291: 113239.
|
| [18] |
Fornaro M, Caiazza C, Pistone L, et al. Atypical depression and emotion dysregulation: clinical and psychopathological features[J]. J Affect Disord, 2025, 376: 410-421.
|
| [19] |
Magen E L, Geishin A, Weizman A, et al. High rates of mood disorders in patients with chronic idiopathic eosinopenia[J]. Brain Behav Immun Health, 2024, 40: 100847.
|
| [20] |
Belanger H G, Lee C, Poliacoff Z, et al. Early response to antidepressant medications in adults with major depressive disorder: a naturalistic study and odds of remission at 14 weeks[J]. J Clin Psychopharmacol, 2023, 43(1): 46-54.
|
| [21] |
Spanagel R, Pendyala G, Abarca C, et al. The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption[J]. Nat Med, 2005, 11(1): 35-42.
|
| [22] |
Olivier B, Olivier J D A. Efficacy, safety, and tolerability of psychedelics in treatment-resistant depression (TRD)[M]//Kim Y K.Recent advances and challenges in the treatment of major depressive disorder. Singapore: Springer Nature Singapore, 2024: 49-66.
|
| [23] |
Milaneschi Y, Lamers F, Berk M, et al. Depression heterogeneity and its biological underpinnings: toward immunometabolic depression[J]. Biol Psychiatry, 2020, 88(5): 369-380.
|
| [24] |
Refisch A, Sen Z D, Klassert T E, et al. Microbiome and immuno-metabolic dysregulation in patients with major depressive disorder with atypical clinical presentation[J]. Neuropharmacology, 2023, 235: 109568.
|
| [25] |
Chae W R, Baumert J, Nübel J, et al. Associations between individual depressive symptoms and immunometabolic characteristics in major depression[J]. Eur Neuropsychopharmacol, 2023, 71: 25-40.
|
| [26] |
Applewhite B, Penninx B W J H, Young A H, et al. The effect of a low-calorie diet on depressive symptoms in individuals with overweight or obesity: a systematic review and meta-analysis of interventional studies[J]. Psychol Med, 2024, 54(8): 1671-1683.
|
| [27] |
Adewuya A O, Coker O A, Atilola O, et al. Gender difference in the point prevalence, symptoms, comorbidity, and correlates of depression: findings from the Lagos State Mental Health Survey (LSMHS), Nigeria[J]. Arch Women's Ment Health, 2018, 21(6): 591-599.
|
| [28] |
Kim J H, Cho M J, Hong J P, et al. Gender differences in depressive symptom profile: results from nationwide general population surveys in Korea[J]. J Korean Med Sci, 2015, 30(11): 1659.
|
| [29] |
Tran K, Mcgill S C, Horton J. Bupropion for treatment-resistant depression[J]. Cjht, 2021, 1(4): 7-17.
|
| [30] |
Patarroyo-Rodriguez L, Pazdernik V, Vande Voort J L, et al. Hypersomnia as a predictor of response to intravenous ketamine/intranasal esketamine in treatment resistant depression[J]. J Affect Disord, 2024, 349: 272-276.
|
| [31] |
Badini I, Coleman J R I, Hagenaars S P, et al. Depression with atypical neurovegetative symptoms shares genetic predisposition with immuno-metabolic traits and alcohol consumption[J]. Psychol Med, 2022, 52(4): 726-736.
|
| [32] |
Younis I R, Gopalakrishnan M, Mathis M, et al. Association of end point definition and randomized clinical trial duration in clinical trials of schizophrenia medications[J]. JAMA Psychiatry, 2020, 77(10): 1064.
|
| [33] |
Robillard R, Carpenter J S, Feilds K L, et al. Parallel changes in mood and melatonin rhythm following an adjunctive multimodal chronobiological intervention with agomelatine in people with depression: a proof of concept open label study[J]. Front Psychiatry, 2018, 9: 624.
|
| [34] |
Geoffroy P A, Palagini L. Biological rhythms and chronotherapeutics in depression[J]. Prog Neuro Psychopharmacol Biol Psychiatry, 2021, 106: 110158.
|
| [35] |
Chung K F, Lee C T, Au C H, et al. Cognitive behavioural therapy for insomnia as an early intervention of mood disorders with comorbid insomnia: a randomized controlled trial[J]. Early Interv Psychiatry, 2024, 18(2): 82-93.
|
| [36] |
Tamaki K, Saito N, Tomita H. Serum 3-hydroxybutyrate is expected to serve as one of the supportive diagnostic markers of persistent idiopathic dentoalveolar pain (PDAP)[J]. J Pain Res, 2023, 16: 4005-4013.
|
| [37] |
Morita Y, Takahashi K, Ohshima S, et al. Is vestibular Meniere's disease associated with endolymphatic hydrops?[J]. Front Surg, 2020, 7: 601692.
|
| [38] |
Munagama C L, Rajendiran V, Silva S. A case report on a common tumour with an uncommon presentation: glioblastoma[J]. Cureus,2024, 16(8): e66830.
|
| [39] |
Said O, Stringer D, Sengun Filiz E, et al. Olanzapine for young PEople with aNorexia nervosa (OPEN): results of a feasibility study[J]. BMC Psychiatry, 2024, 24(1): 779.
|